Topic: Cancer treatment
Associate Professor Holst’s team have been working on a new type of anti-cancer drug that can ‘starve’ prostate cancer cells and stop their growth.
Resistance to endocrine therapies is common, affecting around 40% of people who undergo treatment for breast cancer. Dr Caldon’s team investigated the underlying causes of this resistance.
Professor De Fazio’s team investigated a rare and treatment-resistant subtype of ovarian cancer. Their approach has a better chance of predicting which treatments will work.
This project is a critical step to expand treatment options and could also pave the way for development of immune therapies for breast cancer.
If the project is successful, it would be one of the first targeted treatments for triple-negative breast cancer, with potential for improved survival rates.
This project aims to find out how certain immune cells could be controlled and how they might be used to predict who will respond to immunotherapy.
The aim of this project is to discover which melanoma patients will benefit the most from the use of BET inhibitor drug treatment.
If successful, this study should significantly improve the patient care of those suffering with advanced liver cancer by making drug treatment more effective.
This project aims to reduce the duration, cost and complications of fungal infections, with a significant reduction in cancer patients suffering.
This project is focused on overcoming the problem of relapse of melanoma in patients being treated by immunotherapy with checkpoint inhibitors.